Back to top
more

Sucampo Pharmaceuticals, Inc. (SCMP)

(Real Time Quote from BATS)

$18.00 USD

18.00
NA

+0.05 (0.28%)

Updated Feb 13, 2018 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mallinckrodt (MNK) Tops on Earnings in Transition Quarter

by Zacks Equity Research

Mallinckrodt Public Limited Company (MNK) reported positive results for the transition quarter (Oct 1, to Dec 30, 2016) beating both sales and earnings expectations.

    Auris (EARS) Expands Pipeline with Intranasal Betahistine

    by Zacks Equity Research

    Auris (EARS) announced that it has strengthened its pipeline by the addition of AM-125 as the third clinical-stage program, which allowed it to expand into the field of vestibular disorders.

      Portola, HealthCare Royalty Partners Ink $150 Million Deal

      by Zacks Equity Research

      Portola (PTLA) announced that it has signed a royalty agreement with HealthCare Royalty Partners (HCR) for $150 million.

        AMAG Down Despite Positive Data on Makena Auto-Injector

        by Zacks Equity Research

        AMAG Pharmaceuticals (AMAG) announced positive top-line results from its pharmacokinetic (PK) study on Makena, subcutaneous auto-injector.

          Novartis (NVS) Votubia Gets EU Approval for Label Expansion

          by Zacks Equity Research

          Novartis (NVS) wins EU approval for label expansion of Votubia in refractory partial-onset seizures in patients with tuberous sclerosis complex.

            Catabasis Hits 52-Week Low on Poor DMD Drug Study Data

            by Zacks Equity Research

            Catabasis (CATB) announced disappointing top-line safety and efficacy data from part B of the MoveDMD study (phase I/II) on edasalonexent (CAT-1004).

              Eli Lilly (LLY) Misses on Q4 Earnings, Beats on Revenues

              by Zacks Equity Research

              Eli Lilly (LLY) reported fourth quarter earnings of 95 cents on revenues of $5.76 billion.

                Mylan (MYL) Gets Favorable Verdict for Copaxone in the US

                by Zacks Equity Research

                Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the company pertaining to claims related to Teva Pharmaceutical's (TEVA) Copaxone 40mg/mL.

                  Exelixis Inks Partnership with Takeda for Cabometyx in Japan

                  by Zacks Equity Research

                  Exelixis (EXEL) and Takeda (TKPYY) entered into an exclusive licensing agreement for the commercialization and clinical development of Cabometyx in Japan.

                    Endo (ENDP) Restructures Branded Pharmaceutical Unit (revised)

                    by Zacks Equity Research

                    Endo International plc (ENDP) announced that it has begun restructuring its corporate and branded pharmaceutical R&D functions in Malvern, PA and Chestnut Ridge, NY.

                      Celgene (CELG) Gets Favorable CHMP Opinion for Revlimid

                      by Zacks Equity Research

                      Celgene Corporation (CELG) announced that the EMA's CHMP has rendered a positive opinion for oncology drug Revlimid as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma.

                        Ironwood/Astellas Report Positive Phase III Data on Linzess

                        by Zacks Equity Research

                        Ironwood (IRWD) and partner Astellas reported positive top-line data from a phase III study on Linzess in adults with chronic constipation.

                          AbbVie (ABBV) Q4 Earnings Meet Estimates, Revenues Lag

                          by Zacks Equity Research

                          AbbVie (ABBV) reported earnings of $1.20 in the fourth-quarter of 2016, with revenues coming in at $6.80 billion.

                            Endo (ENDP) Restructures its Branded Pharmaceutical Unit

                            by Zacks Equity Research

                            Endo International plc (ENDP) announced that it has begun restructuring its corporate and branded pharmaceutical R&D functions in Malvern, PA and Chestnut Ridge, NY.

                              Celgene (CELG) Misses on Earnings & Revenues, Keeps View

                              by Zacks Equity Research

                              Celgene (CELG) reported fourth-quarter 2016 earnings of $1.41 per share (including share-based compensation expense and tax adjustments), missing the Zacks Consensus Estimate of $1.43.

                                Roche (RHHBY) Arthritis Drug Actemra sBLA Accepted by FDA

                                by Zacks Equity Research

                                Roche's (RHHBY) supplemental Biologics License Application (sBLA) for arthritis drug, Actemra, accepted for review by the FDA for giant cell arteritis (GCA).

                                  Novartis (NVS) Beats Q4 Earnings, Might Spin-Off Alcon

                                  by Zacks Equity Research

                                  Novartis' (NVS) fourth-quarter 2016 results were mixed with the company beating earnings estimates but missing on revenues. The company has been facing challenging conditions for the past few quarters.

                                    Sunesis Offers Updates on SNS-062 and Qinprezo Programs

                                    by Zacks Equity Research

                                    Sunesis (SNSS) provided updates on two of its lead programs: SNS-062, and Qinprezo (vosaroxin).

                                      Eagle Pharmaceuticals Wraps Up Ryanodex NDA Submission

                                      by Zacks Equity Research

                                      Eagle (EGRX) announced that it has completed the submission of its 505(b)(2) NDA in the U.S. for Ryanodex for the treatment of exertional heat stroke.

                                        Gilead (GILD) HCV Therapy Application Validated in Europe

                                        by Zacks Equity Research

                                        Gilead Sciences, Inc. (GILD) announced that its MAA for once-daily, single tablet regimen of Sovaldi, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for HCV treatment has been fully validated.

                                          Bristol-Myers Settles Litigation with Merck for Keytruda

                                          by Zacks Equity Research

                                          Bristol-Myers Squibb Company (BMY) along with partner Ono Pharmaceutical Company, Ltd. announced that both the companies have signed a global patent license agreement with Merck & Co., Inc. (MRK) to settle all litigation related to Keytruda.

                                            Prima Biomed Initiates Randomized Study for Breast Cancer

                                            by Zacks Equity Research

                                            Prima (PBMD) dosed the first patient in the enlarged randomized phase of the phase IIb study -- AIPAC -- on IMP321 for the treatment of metastatic breast cancer.

                                              Synergy (SGYP) Trulance Wins FDA Approval for Constipation

                                              by Zacks Equity Research

                                              Synergy Pharmaceuticals Inc. (SGYP) announced that the FDA has approved one of its lead pipeline candidates, Trulance (plecanatide), for the treatment of adults suffering from chronic idiopathic constipation (CIC).

                                                Allergan (AGN) Rhofade Cream for Rosacea Approved in U.S.

                                                by Zacks Equity Research

                                                Allergan plc (AGN) announced that the FDA has approved Rhofade (oxymetazoline hydrochloride) cream for topical treatment of persistent facial erythema (redness) associated with rosacea in adults.

                                                  Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico

                                                  by Zacks Equity Research

                                                  Apricus (APRI) announced that Vitaros was approved in Mexico for the treatment of patients with erectile dysfunction.